AVLNAvalyn Pharma Inc.同业对比
Avalyn Pharma Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVLN本股 | $1.5B#7 | — | 3.9x#8 | — | — | — | — | 0.0%#3 | — | — | — | — |
| XNCR | $1.8B#1 | — | 3.5x#6 | 14.0x#5 | 13.7%#7 | 60.5%#5 | -141.4%#6 | -18.3%#9 | -31.5%#5 | — | 174.9%#4 | — |
| ANIP | — | 16.1x#4 | — | — | 43.8%#4 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#2 | — | -24.5%#12 | — |
| KLRA | $1.6B#2 | — | 1.5x#2 | — | — | — | — | 0.0%#3 | — | — | — | — |
| KARD | $1.6B#3 | — | 2.6x#3 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ETON | $1.6B#4 | — | 34.6x#12 | 20.1x#6 | 104.9%#3 | -20.4%#8 | -1.1%#5 | -9.9%#8 | -1.8%#4 | 4#2 | 220.3%#2 | — |
| ANAB | $1.6B#5 | — | 124.0x#14 | 6.7x#3 | 157.0%#2 | 90.9%#4 | 20.4%#2 | -103.8%#14 | — | — | 180.0%#3 | — |
| SNDX | $1.5B#6 | — | 102.1x#13 | 8.9x#4 | 627.8%#1 | 10.5%#7 | -158.4%#7 | -1890.2%#15 | -1205.8%#6 | — | 14.9%#9 | — |
| INVA | $1.5B#8 | 4.9x#3 | 1.2x#1 | 3.7x#1 | 14.7%#6 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#3 | 5#1 | 9.8%#10 | — |
| DMRA | $1.5B#9 | 3.2x#2 | 2.9x#4 | — | — | -878.8%#12 | — | -40.7%#12 | — | — | 751.8%#1 | — |
| BCAX | $1.5B#10 | — | 3.1x#5 | — | — | -102.9%#10 | — | -29.4%#10 | — | — | 95.6%#7 | — |
| TYRA | $1.5B#11 | — | 4.1x#9 | — | — | -38.7%#9 | — | -33.9%#11 | — | — | 96.4%#6 | — |
| XERS | $1.4B#12 | — | — | 4.9x#2 | 43.7%#5 | 101.0%#3 | 8.5%#4 | — | 20.6%#1 | — | 4.4%#11 | — |
| TRAX | $1.4B#13 | — | 8.3x#11 | — | — | — | — | 0.0%#3 | — | — | — | — |
| LBRX | $1.4B#14 | 1.9x#1 | 4.1x#10 | — | — | 60.1%#6 | — | -7.6%#7 | — | — | 170.5%#5 | — |
| AVBP | $1.4B#15 | — | 3.7x#7 | — | — | -106.6%#11 | — | -45.3%#13 | — | — | 52.3%#8 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议